CRBP on Nasdaq

Corbus Pharmaceuticals

Logo: corbuspharma.com4

American pharmaceutical company based in Norwood, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Jan 1, 2009Founded1

Compare with Aeglea BioTherapeutics, Rallybio or Neurogene Inc., or pick any stock.

  • TickerCRBP on Nasdaq1
  • Industrypharmaceutical industry1
  • HeadquartersNorwood1
  • Websitecorbuspharma.com
  • Incorporated inDE5
  • Business address500 River Ridge Drive, Norwood, Ma 020625
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • Legal formCorporation3
  • LEI529900MX6XCNZC7MM1553
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressc/o COGENCY GLOBAL INC., 850 NEW BURTON ROAD SUITE 201, 19904 Dover, United States3
  • Registered withDivision of Corporations, Department of State, 54519153

See how the biggest companies compare on our leaderboards

All references in this report to “Corbus,” the “Company,” “we,” “us,” or “our” mean Corbus Pharmaceuticals Holdings, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates.6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-100.0%Revenue growth, 20227
-128.4%Return on equity8
0.48×Debt to equity9
-$37.6MFree cash flow9

Financial statements

Revenue10117$0 in 2022
0$10.0M$20.0M$30.0M$40.0M2019: $36.1M$36.1M20192020: $3.9M$3.9M2020−89%2021: $881.7K$881.7K2021−78%2022: $0$02022
Operating income101179-$39.8M in 2022−48% since 2019
-$150.0M-$100.0M-$50.0M02019: -$77.1M-$77.1M20192020: -$122.8M-$122.8M2020+59%2021: -$56.0M-$56.0M2021−54%2022: -$39.8M-$39.8M2022−29%
Net income101179-$42.3M in 2022−41% since 2019
-$150.0M-$100.0M-$50.0M02019: -$71.5M-$71.5M20192020: -$111.3M-$111.3M2020+56%2021: -$45.6M-$45.6M2021−59%2022: -$42.3M-$42.3M2022−7%

Every line of the income statement as filed: the last 2 fiscal years, latest first.14

Period ending2025-12-312024-12-31
Research and development$70.1M$32.2M
General and administrative$15.2M$16.5M
Total operating expenses$85.3M$48.7M
Operating loss-$85.3M-$48.7M
Interest and investment income, net$5.5M$6.3M
Interest expense$0-$1.9M
Other income, net$1.2M$4.1M
Total other income, net$6.8M$8.5M
Net loss-$78.5M-$40.2M
Net loss per share, basic-$5.90-$3.68
Net loss per share of common stock diluted-$5.90-$3.68
Weighted average number of common shares outstanding, basic13.3M shares10.9M shares
Weighted average number of common shares outstanding, diluted13.3M shares10.9M shares
Net Income (Loss)-$78.5M-$40.2M
Change in unrealized (loss) gain on marketable debt securities-$88.0K$36.0K
Total other comprehensive (loss) income-$88.0K$36.0K
Total comprehensive loss-$78.6M-$40.2M

Compare Corbus Pharmaceuticals with another company

Leadership

Who has led Corbus Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

President

  1. Mark Tepper2014–2019

Chief operating officer

  1. Robert Paul Discordia2019–2020
  2. Craig Stuart Millian2022–2023
  3. Ian Hodgson2025–now
2010201520202025
Board members and other officers (18)

Former names

  • SAV Acquisition CorpJan 10, 2014 to Jan 10, 20145

Timeline

  1. Jan 1, 2009Founded Founded1

Filings

312 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 81 major events, 111 insider forms, 37 large holders, 62 other. The latest 20:

  1. Oct 15, 20268-K EDGAR
  2. Sep 30, 2026SCHEDULE 13G EDGAR
  3. Sep 15, 20264 EDGAR
  4. Sep 14, 20268-K EDGAR
  5. Aug 17, 20264 EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 12, 20264 EDGAR
  8. Aug 10, 20264 EDGAR
  9. Aug 10, 20264 EDGAR
  10. Aug 7, 2026144 EDGAR
  11. Aug 7, 2026144 EDGAR
  12. Aug 7, 2026424B5 EDGAR
  13. Aug 6, 202610-Q EDGAR
  14. Aug 6, 20268-K EDGAR
  15. Aug 4, 20263 EDGAR
  16. Jul 27, 2026SCHEDULE 13G EDGAR
  17. Jul 27, 2026144 EDGAR
  18. Jul 6, 20268-K EDGAR
  19. Jun 17, 2026S-8 EDGAR
  20. Jun 11, 20264 EDGAR

The 312 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

44 open-market trades by officers, directors and large owners since October 2021: 16 buys and 28 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 14, 2026Ben YongDirectorSale2,000$7.84$15.7KForm 4
Aug 11, 2026Saxena Nishant CChief Business OfficerBuy2,600$9.63$25.0KForm 4
Aug 7, 2026Cohen YuvalChief Executive OfficerSale17,000$10.08$171.4KForm 4
Aug 7, 2026Moran Sean F.Chief Financial OfficerSale12,000$10.08$121.0KForm 4
Jun 10, 2026Kung WinstonDirectorSale2,026$7.91$16.0KForm 4
Jun 10, 2026Jenkins John KennethDirectorSale4,800$7.91$38.0KForm 4
Jun 10, 2026Altmeyer AnneDirectorSale2,412$7.91$19.1KForm 4
Jun 3, 2026Saxena Nishant CChief Business OfficerBuy9,000$7.58$68.2KForm 4
Jun 2, 2026Saxena Nishant CChief Business OfficerBuy4,500$7.33$33.0KForm 4
Mar 2, 2026Smethurst DominicChief Medical OfficerSale6,097$8.30$50.6KForm 4
Feb 17, 2026Hodgson IanChief Operating OfficerSale847$7.38$6.3KForm 4
Feb 13, 2026Moran Sean F.Chief Financial OfficerSale4,701$7.78$36.6KForm 4
Feb 13, 2026Cohen YuvalChief Executive OfficerSale13,871$7.78$107.9KForm 4
Feb 3, 2026Smethurst DominicChief Medical OfficerSale3,285$8.09$26.6KForm 4
Feb 3, 2026Hodgson IanChief Operating OfficerSale2,415$8.09$19.5KForm 4
Dec 11, 2025Chen Bihua10% ownerSale30,029$11.46$344.1KForm 4
Oct 27, 2025Cohen YuvalChief Executive OfficerSale8,973$17.14$153.8KForm 4
Oct 24, 2025Cohen YuvalChief Executive OfficerSale18,660$17.01$317.4KForm 4
Oct 24, 2025Moran Sean F.Chief Financial OfficerSale12,981$17.02$220.9KForm 4
Oct 20, 2025Altmeyer AnneDirectorSale1,060$20.50$21.7KForm 4

All 44 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Cormorant Asset Management, LP2,344,971$22.0M1.1%No change
Orbimed Advisors LLC1,737,287$16.3M0.3%No change
BlackRock, Inc.1,331,135$12.5M0.0%+1,059,499
Aberdeen Group plc1,321,750$12.4M0.0%No change
Vanguard Capital Management LLC760,940$7.1M0.0%+26,834
Jones Hill Capital LP653,572$6.1M1.3%New
Prosight Management, LP650,000$6.1M1.1%−47,108
Stonepine Capital Management, LLC425,000$4.0M3.0%+41,538
Geode Capital Management, LLC423,374$4.0M0.0%+236,345
ADAR1 Capital Management, LLC421,787$4.0M0.2%+90,006
Diadema Partners LP301,264$2.8M1.1%−138,693
Susquehanna International Group, Llp293,203$2.8M0.0%−40,212
State Street Corp254,672$2.4M0.0%+185,800
Dimensional Fund Advisors LP190,214$1.8M0.0%+53,612
Exome Asset Management LLC184,914$1.7M1.1%−49,222
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.151,640$1.4M0.0%−8,822
Jane Street Group, LLC139,133$1.3M0.0%+65,940
Northern Trust Corp124,906$1.2M0.0%+83,402
Vanguard Fiduciary Trust Co112,397$1.1M0.0%+16,156
Vanguard Portfolio Management LLC111,302$1.0M0.0%+86,937
Renaissance Technologies LLC110,822$1.0M0.0%−236,176
DAFNA Capital Management LLC107,773$1.0M0.2%New
Citadel Advisors LLC92,154$864.4K0.0%−634,906
Advisory Services Network, LLC89,951$843.7K0.0%+89,937
Cantor Fitzgerald, L. P.80,196$752.2K0.0%+40,098

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55